X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA GSK PHARMA SHASUN PHARMA/
GSK PHARMA
 
P/E (TTM) x 123.9 66.8 185.4% View Chart
P/BV x 8.5 11.7 72.8% View Chart
Dividend Yield % 0.2 1.1 21.6%  

Financials

 SHASUN PHARMA   GSK PHARMA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
GSK PHARMA
Mar-17
SHASUN PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs943,838 2.5%   
Low Rs462,637 1.7%   
Sales per share (Unadj.) Rs214.2354.2 60.5%  
Earnings per share (Unadj.) Rs5.339.8 13.4%  
Cash flow per share (Unadj.) Rs15.842.9 36.9%  
Dividends per share (Unadj.) Rs1.0030.00 3.3%  
Dividend yield (eoy) %1.40.9 154.4%  
Book value per share (Unadj.) Rs53.3236.9 22.5%  
Shares outstanding (eoy) m56.6284.70 66.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.39.1 3.6%   
Avg P/E ratio x13.181.4 16.1%  
P/CF ratio (eoy) x4.475.5 5.9%  
Price / Book Value ratio x1.313.7 9.6%  
Dividend payout %18.775.4 24.8%   
Avg Mkt Cap Rs m3,958274,216 1.4%   
No. of employees `000NA4.7 0.0%   
Total wages/salary Rs m2,1644,830 44.8%   
Avg. sales/employee Rs ThNM6,387.0-  
Avg. wages/employee Rs ThNM1,028.3-  
Avg. net profit/employee Rs ThNM717.1-  
INCOME DATA
Net Sales Rs m12,12730,000 40.4%  
Other income Rs m229728 31.5%   
Total revenues Rs m12,35630,728 40.2%   
Gross profit Rs m1,0094,190 24.1%  
Depreciation Rs m594263 225.7%   
Interest Rs m4150-   
Profit before tax Rs m2304,655 4.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m-731,744 -4.2%   
Profit after tax Rs m3023,368 9.0%  
Gross profit margin %8.314.0 59.6%  
Effective tax rate %-31.737.5 -84.5%   
Net profit margin %2.511.2 22.2%  
BALANCE SHEET DATA
Current assets Rs m6,88416,742 41.1%   
Current liabilities Rs m8,4567,202 117.4%   
Net working cap to sales %-13.031.8 -40.8%  
Current ratio x0.82.3 35.0%  
Inventory Days Days6252 119.0%  
Debtors Days Days10821 517.5%  
Net fixed assets Rs m4,9708,635 57.6%   
Share capital Rs m113847 13.4%   
"Free" reserves Rs m2,87519,222 15.0%   
Net worth Rs m3,02020,069 15.0%   
Long term debt Rs m1,81710 18,174.0%   
Total assets Rs m13,34730,038 44.4%  
Interest coverage x1.6NM-  
Debt to equity ratio x0.60 120,762.2%  
Sales to assets ratio x0.91.0 91.0%   
Return on assets %5.411.2 47.9%  
Return on equity %10.016.8 59.6%  
Return on capital %13.325.5 52.3%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,843528 1,106.6%   
Fx outflow Rs m2,1737,193 30.2%   
Net fx Rs m3,669-6,665 -55.1%   
CASH FLOW
From Operations Rs m3982,360 16.8%  
From Investments Rs m-1,6353,008 -54.4%  
From Financial Activity Rs m1,309-5,108 -25.6%  
Net Cashflow Rs m71260 27.4%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 3.6 10.2 35.3%  
FIIs % 17.6 23.8 73.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 15.4 257.1%  
Shareholders   20,750 102,036 20.3%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS